Pneumonia, a largely preventable disease, caused more than two million deaths in 2021, according to the Global Burden of ...
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
The first evaluable patient in Cohort 2 (Patient 6) demonstrated a clear dose response, and early MyBP-C expression increased by 14% after only 12 weeks post-dose. Of note, Patient 6 had a greater ...
An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.
Pioneering CRISPR trial shows single infusion permanently lowers bad cholesterol by 50% in patients who don't respond to medication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback